Technology
Headlines surrounding the Videotron case occurring during a broad market sell-off has created a deep discount in XPER's valuation - however, the patent lawsuits in Canada are just one of several catalysts that could develop in 2022 and were not included in Hamed Khorsand’s earnings model. Investors should instead focus on XPER’s expanding end markets and the company’s ability to generate revenue from new automobile models incorporating AutoSense in Europe. Hamed estimates FCF of $200m in 2022 (FCF yield of ~14%) and even more in 2023. TP $26 (85% upside).
Edition: 138
- 24 June, 2022
Technology
Hamed Khorsand’s new “Top Pick” XPER is certainly worth a closer look given his previous choice (Verso) multi-bagged since upgrading the stock in Oct 2020. XPER offers multiple ways to grow revenue in the coming years, from AutoStage and AutoSense to hybrid bonding and content streaming intellectual property. Currently trading at ~10% FCF yield, XPER has been dedicating 50% of its FCF to debt reduction and the other 50% to returning cash to shareholders. As net debt continues to fall Hamed expects the stock to garner more investor attention this year.
Edition: 127
- 21 January, 2022
Event-Driven Legal℠ Investment-Research Opportunities
MDC’s “Event-Driven Legal℠” investment-research service follows significant legal disputes to provide clients with actionable investment ideas that tend to be non-correlated with the market. MDC has been providing its subscription “Event‐Driven Legal℠” investment‐research service since 2009. Typically, MDC keeps ~50 active cases on its Focus List and provides clients with breaking news/predictions during proceedings and analysis on important orders swiftly upon the Court publishing such information to its Docket. Current coverage includes: Amarin Pharma, Amgen, Biogen, Bristol-Myers Squibb, Catalyst Pharmaceuticals, Qualcomm, Renren and Xperi.
Edition: 116
- 06 August, 2021